EVANS CITY, Pa., May 3, 2017 /PRNewswire/ -- Callery Corporation ("Callery") today announces
Dr. Rathore holds a Ph.D. in Medicinal Chemistry from the Oregon State University. Early in his career, he founded a specialty pharma chemical company, Polyorganix. The company was later acquired by Borregaard Synthesis, where he remained in an executive capacity for several years. His professional career also includes key executive roles at leading global companies, such as Lonza AG and Alcami Corporation. Previously, Dr. Rathore served as a board member of Borregaard Synthesis and Suven Life Sciences, and currently serves on the board of ZCL Chemicals.
"I'm delighted to be part of an organization with such a rich history and a bright future," said Dr. Rathore. "The company's products have enabled some of the world's most impressive innovations, including billion-dollar blockbuster drugs, agricultural chemicals, and other high performance products from electronics to polymer applications. I look forward to leading Callery into the next phase of its growth and success."
Bob Girton, Principal at Edgewater Capital and member of Callery's Board of Directors, said: "Harry has the perfect combination of industry knowledge, commercial experience and relationships, technical expertise, and a proven track record in leading innovative chemistry organizations. We are excited for the growth and success Harry and the Callery team will bring to the business. Callery is a great addition to our portfolio of performance materials companies with a common commercial theme of customer focus, technical service, and solution oriented sales."
About CalleryCallery, formerly BASF's Inorganic Specialties Business, is the world's leading expert in alkoxide bases, borane derivatives, and other highly reactive chemistries. Headquartered in Evans City, Pennsylvania, Callery prides itself in enabling its customers' success with world-class innovators, unmatched quality, flexible production options, outstanding customer service, and global supply chain management. Callery's products enable some of the world's most successful innovations from billion-dollar blockbuster drugs to next-generation OLEDs. How can Callery's capabilities enable your next big innovation? Further information at www.callery.com.
PR Contact: Andy Fritts, CEO, FH Group, firstname.lastname@example.org, 814-459-2443
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-harry-rathore-appointed-callery-corporations-ceo-300450277.html
SOURCE Callery Corporation
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All